Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.64 Analyst target: $6.17 Upside: 864.82%
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.
See the full interactive analysis & chart →Informational only — not investment advice.